Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm, Immunexpress and Biocartis Announce Collaboration

Published: Wednesday, December 26, 2012
Last Updated: Wednesday, December 26, 2012
Bookmark and Share
Collaboration to advance development of SeptiCyte® Triage for managing sepsis.

Debiopharm Group™ (Debiopharm), Immunexpress Group and Biocartis have announced a world-wide exclusive, royalty-bearing license for the late-stage development and commercialization of SeptiCyte® Triage - a multiplex gene expression assay for use in Emergency and Intensive Care Units (ICUs) or upon hospital admission to diagnose sepsis early, differentiate sepsis from other forms of inflammation, and determine sepsis severity.

Under the terms of the agreement, Debiopharm will fund the validation and U.S. Food and Drug Administration (FDA) clearance of SeptiCyte® Triage and Biocartis will subsequently fund the development and commercialization of the validated SeptiCyte® Triage assay on its fully integrated molecular diagnostics platform.

This platform - which includes an instrument, communication console, and single use, disposable cartridges - can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with minimal user intervention in less than 90 minutes.

As part of the agreement, Debiopharm will complete an equity investment in Immunexpress of AUD 2 million.

“The synergy created by this partnership is not only important for the continued development and future availability of SeptiCyte® Triage - but it also exemplifies Immunexpress’ commitment to innovative science and partnerships that improve outcomes for clinicians and patients”, said Dr Roslyn Brandon, President and CEO, Immunexpress.

Dr Brandon continued, “With accuracy significantly better than procalcitonin, bringing SeptiCyte® Triage onto Biocartis’ revolutionary point-of-need multiplex qRT-PCR platform will enable clinicians to more quickly and accurately identify and triage patients suspected of sepsis».

Greg Parekh, Biocartis’ CEO, commented: “Biocartis is striving to bring more effective, individualized treatments within reach of patients through the availability of high quality diagnostics at the point of need. Sepsis is a major cause of death where timely accurate diagnostic information can make a significant difference in medical outcomes”.

“Debiopharm is enthusiastic to join forces with Immunexpress and Biocartis and to take an additional step in our strong commitment to personalized medicine”, said Thierry Mauvernay, Debiopharm’s delegate of the board, who added, “The collaboration opens the door to exploit synergies between the three companies by addressing this life-threatening condition from different perspectives, particularly from a health economics one. Supporting better management of sepsis may ultimately lead to a reduction in mortality, better outcomes and possibly the discovery of new therapies”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

FDA Grants Orphan Drug Designation to Debio 1143
Company grants FDA designation to Debio 1143 for the treatment of ovarian cancer.
Thursday, June 02, 2016
Debiopharm and EORTC Announce a Collaboration
Collaboration to investigate triptorelin for treatment of salivary gland cancers.
Thursday, January 14, 2016
EMA Grants Orphan Drug Designation to Debio 1143
Company grants EMA Designation to Debio 1143 for treatment of Ovarian Cancer.
Thursday, December 10, 2015
United and Debiopharm Announce the Launch of Pamorelin®
Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines.
Tuesday, December 08, 2015
Debiopharm’s Partner Yakult Announces Elplat® Approbation in Gastric Cancer
Approval for a supplemental new drug application for Elplat® in postoperative adjuvant chemotherapy in Japan.
Saturday, November 28, 2015
JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award
The ‘JCA-Mauvernay Award 2015’ is awarded to Doctors Yutaka Kondo and Junko Takita.
Saturday, October 10, 2015
Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
Company presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347.
Tuesday, April 21, 2015
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
Trelstar® one-, three-, and six-month dosing options now available.
Wednesday, October 08, 2014
Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Curis and Debiopharm Report Preclinical Data for Debio 0932
Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
Wednesday, April 09, 2014
Experimental Therapeutics Centre and Debiopharm Group™ to Collaborate
Collaboration for the development of an epigenetic innovative oncology target.
Tuesday, October 08, 2013
Diagnoplex S.A. Closes a Financing Round Led by Debiopharm Group™
Diagnoplex secures 1.3 million Swiss francs from financing round.
Friday, June 07, 2013
Debiopharm Group to Support Ascepion in the Development of Debio 1144
Development of Debio 1144 for the treatment of Chinese cancer patients.
Thursday, April 18, 2013
Chugai and Debiopharm Announce an Exclusive License Agreement for FF284
Chugai will grant Debiopharm an exclusive license to develop and commercialize FF284 in all countries.
Tuesday, January 08, 2013
First Patient Treated in Phase III Study with SC Administration of Debio 8206
Administration of Debio 8206 by SC route will prove very convenient in prostate cancer patients.
Thursday, December 27, 2012
Scientific News
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Modified Yeast Shows Plant Response to Key Hormone
Researchers have developed a toolkit based on modified yeast to determine plant responses to auxin.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
NCI Collaborates with Multiple Myeloma Research Foundation
NCI collaborates with MMRF to incorporate genomic and clinical data into NCI Genomic Data Commons database.
Epigenetic Clock Predicts Life Expectancy
New research finds 5 percent of population ages faster, faces shorter lifespan.
Regulatory RNA Essential to DNA Damage Response
Researchers discover a tumour suppressor is stabilized by an RNA molecule, which helps cells respond to DNA damage.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!